Just reported
From Pfizer's results release of 3 november 2026; its quarterly report has since been filed.
Actual
US$ 16,58B
-0,4% y/y
+10% q/q
Guided
—
No guide given
Actual
US$ 0,56
-9,7% y/y
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Pfizer is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
De omzetaandelen zijn schattingen voor year ended December 31, 2025, high confidence, geen cijfers uit een ingediend rapport.
Eliquis
A prescription medicine that helps prevent blood clots and strokes in certain patients. Pfizer shares its development and commercial profits with Bristol Myers Squibb.
Pfizer vaccine portfolio
Vaccines include the Prevnar family for pneumococcal disease, Comirnaty to help prevent coronavirus disease, and Abrysvo for respiratory syncytial virus.
Paxlovid
A prescription medicine used to treat coronavirus disease.
Oncology medicines
Cancer medicines include Ibrance for breast cancer, Padcev for bladder cancer, and Xtandi for prostate cancer.
Nurtec ODT and Vydura
Migraine medicines. ODT means orally disintegrating tablet.
Vyndaqel family
Medicines for transthyretin amyloidosis, a disease in which an abnormal protein builds up in the body and can damage the heart or nerves.
Pfizer discovers, tests, manufactures, markets and sells medicines and vaccines around the world. Its products address conditions including cancer, heart and blood-vessel diseases, migraine, infections, immune disorders and rare diseases. It also makes medicines and drug ingredients for other companies and is winding down a research-services business for biotechnology companies.
Gebouwd uit de eigen deponeringen van Pfizer Inc. bij de Amerikaanse toezichthouder Securities and Exchange Commission (SEC). De cijfers zijn zoals gerapporteerd, met de historie per aandeel herrekend naar de huidige aandelenbasis. Dit beschrijft een bedrijf — het is geen beleggingsadvies en geen aanbeveling om iets te kopen of te verkopen.
US$ 28,84-2,1%slot 12 nov
Cijfers tot en met 27 september 2026, uit de 10-Q ingediend op 3 november 2026
Pfizer develops, makes and sells prescription medicines and vaccines, and earns additional fees and royalties from manufacturing and commercial partnerships.
Grade C
De balk onder de koers toont het cijfer op elke datum, alleen gebaseerd op de stukken die toen al openbaar waren.
Toont 2 van 41 kwartalen van de cijferhistorie van Pfizer Inc.. De andere 39 lopen terug tot november 2016.